



(12) Translation of
european patent specification

(11) NO/EP 2740731 B1

NORWAY

(19) NO
(51) Int Cl.
C07D 487/04 (2006.01)
A61K 31/519 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2016.07.25
(80)	Date of The European Patent Office Publication of the Granted Patent	2016.03.23
(86)	European Application Nr.	13198120.1
(86)	European Filing Date	2008.06.12
(87)	The European Application's Publication Date	2014.06.11
(30)	Priority	2007.06.13, US, 943705 P
(84)	Designated Contracting States:	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MT NL NO PL PT RO SE SI SK TR
	Designated Extension States:	AL BA MK RS
(62)	Divided application	EP2173752, med inndato 2008.06.12
(73)	Proprietor	Incyte Holdings Corporation, 1801 Augustine Cut-Off, Wilmington, DE 19803, US-USA
(72)	Inventor	LI, Hui-Yin, 176 Thompson Drive, Hockessin, DE Delaware 19707, US-USA RODGERS, James, D., 2 Hillside Lane, Landenberg, PA Pennsylvania 19350, US-USA
(74)	Agent or Attorney	Oslo Patentkontor AS, Postboks 7007 Majorstua , 0306 OSLO, Norge

(54)	Title	CRYSTALLINE SALTS OF THE JANUS KINASE INHIBITOR (R)-3-(4-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)-1H-PYRAZOL-1-YL)-3-CYCLOPENTYLPROPANENITRILE
(56)	References Cited:	WO-A-01/42246 WO-A-2006/096270 WO-A-2007/070514

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Salt valgt fra gruppen bestående av:

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-fosforsyresalt;

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-svovelsyresalt; og

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-maleinsyresalt;

hvor saltet er krystallinsk.

2. Krystallinsk salt ifølge krav 1, som er (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-fosforsyresalt.

3. Krystallinsk salt ifølge krav 1, som er (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-svovelsyresalt.

4. Krystallinsk salt ifølge krav 1, som er (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-maleinsyresalt.

5. Krystallinsk salt ifølge krav 2, hvor det krystallinske salt er 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril:fosforsyre-salt.

6. Krystallinsk salt ifølge krav 3, hvor det krystallinske salt er 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril:svovelsyre-salt.

7. Krystallinsk salt ifølge krav 4, hvor det krystallinske salt er 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril:maleinsyre-salt.

8. Farmasøytisk formulering omfattende det krystallinske salt ifølge et hvilket som helst av kravene 1 til 7 og en farmasøytisk akseptabel bærer.

9. Doseringsform omfattende et krystallinsk salt valgt fra gruppen bestående av

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-fosforsyresalt,

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-svovelsyresalt, og

(R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropannitril-maleinsyresalt.

10. Doseringsform omfattende en farmasøytisk formulering ifølge krav 8.

11. Doseringsform ifølge krav 9 eller krav 10, hvor doseringsformen er egnet for oral administrasjon.

12. Doseringsform ifølge krav 11, hvor doseringsformen er en tablett.